|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net income (loss) | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Provision for loss on receivables and retained interests in securitization trusts | |||||
| Depreciation and amortization | |||||
| Amortization of financing costs | |||||
| Equity-based expenses | |||||
| Equity method investments | |||||
| Non-cash gain on securitization | |||||
| (Gain) loss on sale of receivables and debt securities | |||||
| Loss on debt extinguishment | |||||
| Changes in receivables held-for-sale | |||||
| Changes in accounts payable, accrued expenses, and other | |||||
| Change in accrued interest on receivables and debt securities | |||||
| Cash received (paid) upon hedge settlement | |||||
| Other | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities | |||||
| Equity method investments | |||||
| Equity method investment distributions received | |||||
| Proceeds from sales of equity method investments | |||||
| Purchases of and investments in receivables ($177 million, $246 million, and $324 million to equity method investees, respectively) | |||||
| Principal collections from receivables ($346 million, $322 million, and $36 million from equity method investees, respectively) | |||||
| Proceeds from sales of receivables | |||||
| Purchases of real estate | |||||
| Proceeds from sale of real estate | |||||
| Purchases of debt securities and retained interests in securitization trusts | |||||
| Proceeds from sales of debt securities and retained interests in securitization trusts | |||||
| Collateral provided to hedge counterparties | |||||
| Collateral received from hedge counterparties | |||||
| Funding of escrow accounts | |||||
| Withdrawal from escrow accounts | |||||
| Other | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from credit facilities | |||||
| Principal payments on credit facilities | |||||
| Proceeds from issuance of commercial paper notes | |||||
| Principal payments on commercial paper notes | |||||
| Proceeds from (repayments of) commercial paper notes | |||||
| Proceeds from issuance of term loan | |||||
| Principal payments on term loan | |||||
| Proceeds from issuance of non-recourse debt | |||||
| Non-recourse debt | |||||
| Principal payments on non-recourse debt | |||||
| Proceeds from issuance of senior notes | |||||
| Principal payments on convertible notes | |||||
| Redemption of senior notes | |||||
| Proceeds from issuances of junior subordinated notes | |||||
| Proceeds from issuance of convertible notes | |||||
| Purchase of capped calls related to the issuance of convertible notes | |||||
| Net proceeds of common stock issuances | |||||
| Payments of dividends and distributions | |||||
| Withholdings on employee share vesting | |||||
| Redemption premium and fees paid | |||||
| Payment of financing costs | |||||
| Collateral provided to hedge counterparties | |||||
| Collateral received from hedge counterparties | |||||
| Other | |||||
| Net cash provided by (used in) financing activities | |||||
| Increase (decrease) in cash, cash equivalents, and restricted cash | |||||
| Cash, cash equivalents, and restricted cash at beginning of period | |||||
| Cash, cash equivalents, and restricted cash at end of period | |||||
| Interest paid | |||||
| Supplemental disclosure of non-cash activity | |||||
| Interest retained from securitization transactions | |||||
| Equity method investments retained from securitization and deconsolidation transactions | |||||
| Right-of-use asset obtained in exchange for lease liability | |||||
| Issuance of common stock from conversion of convertible notes | |||||
| Equity method investments retained from sale of assets to a co-investment structure | |||||
| Deconsolidation of non-recourse debt | |||||
| Deconsolidation of assets pledged for non-recourse debt | |||||
| Assumption of deferred financing obligation | |||||
| Removal of deferred financing obligation upon securitization | |||||
Loading...